DDInter690 DDInter1679
A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in alcoholic beverages.
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255]. Sitagliptin was granted FDA approval on October 16, 2006.
Ethanol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sitagliptin
Ethanol {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Nelfinavir
Nelfinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sitagliptin
Ethanol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is associated with {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Sitagliptin
Ethanol {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Enzalutamide
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sitagliptin
Ethanol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Digoxin
Digoxin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sitagliptin
Ethanol {u} (Compound) binds {v} (Gene) GRIN3A
GRIN3A {u} (Gene) regulates {v} (Gene) SLC38A1
SLC38A1 {u} (Gene) is downregulated by {v} (Compound) Sitagliptin
Ethanol {u} (Compound) binds {v} (Gene) GRIN3A
GRIN3A {u} (Gene) regulates {v} (Gene) SELL
SELL {u} (Gene) is upregulated by {v} (Compound) Sitagliptin
Ethanol {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sitagliptin
Ethanol {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Bexarotene
Bexarotene {u} may lead to a major life threatening interaction when taken with {v} Sitagliptin
Ethanol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sitagliptin (Compound)
Ethanol (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Nelfinavir (Compound) and Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Ethanol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is associated with type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Sitagliptin (Compound)
Ethanol (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Enzalutamide (Compound) and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Ethanol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Digoxin (Compound) and Digoxin may cause a minor interaction that can limit clinical effects when taken with Sitagliptin
Ethanol (Compound) binds GRIN3A (Gene) and GRIN3A (Gene) regulates SLC38A1 (Gene) and SLC38A1 (Gene) is downregulated by Sitagliptin (Compound)
Ethanol (Compound) binds GRIN3A (Gene) and GRIN3A (Gene) regulates SELL (Gene) and SELL (Gene) is upregulated by Sitagliptin (Compound)
Ethanol (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Ethanol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Bexarotene (Compound) and Bexarotene may lead to a major life threatening interaction when taken with Sitagliptin